Search results for: 'cell ad gene manufacturing'

10 Sep 2024  |  Global  |  Technology Research

Technology Advances in Modular and Automated Platforms for Pharmaceutical Manufacturing

Increasing demand for small molecule drugs is driving the growth of modular and automated technologies in pharmaceutical manufacturing

Infographics

×

This study examines technology advances in modular and automated platforms for non-biologics manufacturing in the pharmaceutical sector. There is a growing demand for automated and modular technologies that ensure regulatory compliance, increase productivity, reduce waste, and meet emerging therapeutic requirements such as those of the personalized...

05 Aug 2024  |  Global  |  Technology Research

CGT Research Outlook and Technology Growth Opportunities

CGT Landscape Assessment

Infographics

×

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, a...

20 Aug 2024  |  Global  |  Technology Research

Technological Advances in Regenerative Medicine

Disruptive Technology and a Competitive Landscape Drive Growth in Stem Cell Therapy Research

Infographics

×

Regenerative medicine has evolved significantly and today includes several commercialized stem cell therapies. Researchers have made notable technological developments in stem cell therapies to overcome challenges related to large-scale manufacturing and cell quality. Stem cell research is more focused on induced pluripotent stem cells than on mese...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...